Alnylam’s HELIOS-B Review: Conflicting Insights Analyzed by Lilu Anderson 25.06.2024 Explore conflicting analyst opinions on Alnylam's HELIOS-B data, contrasting efficacy views for vutrisiran in addressing ATTR-CM treatments.
ResMed, Inspire Medical Drop After Lilly’s Zepbound Study by Mark Eisenberg 24.06.2024 "ResMed and Inspire Medical stocks plummet after Eli Lilly's Zepbound trial success; Citi downgrades RMD, sees market shift. Read more ...
VR Center in Hainan Pioneers AI for Marine Conservation by Lilu Anderson 24.06.2024 "New VR Engineering Research Center in Hainan aims to transform education and industry with AI, featuring innovative tech like virtual ...
Numinus Wellness Acquires MedBright AI, Rebrands as Numinus Intelligence by Lilu Anderson 23.06.2024 "Numinus Wellness acquires MedBright AI, merging AI with psychedelics for advanced mental health care and expanded services in the U.S."
Lilly’s Zepbound Resolves Sleep Apnea in 52% of Patients by Mark Eisenberg 22.06.2024 Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
Iontronic Tech Promises Hope in Slowing Malignant Brain Tumors by Lilu Anderson 20.06.2024 "Iontronic tech shows promise in slowing malignant brain tumor growth by continuously delivering low-dose drugs, bypassing the blood-brain barrier."
Biotech’s Big Gamble Fails: Insights and Implications by Lilu Anderson 18.06.2024 Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Virtual Reality Exposure Therapy Market: Transforming Anxiety Treatment by Lilu Anderson 18.06.2024 Discover the booming VRET market, driven by tech advances and mental health needs, expected to grow at a 33.90% CAGR ...
7 Breakthrough Biotech Stocks to Boost Your Portfolio in 2023 by Lilu Anderson 18.06.2024 "Discover 7 breakthrough biotech stocks poised to boost your portfolio in a sector projected to reach $521.6B by 2033. Learn ...
Roche’s Hemlibra Battles Fierce Competition Amid Rating Hold by Mark Eisenberg 17.06.2024 Roche's Hemlibra braces for fierce competition from Novo Nordisk's mim8, as analysts give mixed ratings and forecasts on Roche's strategic ...